Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...
No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more frequently in patients treated with Iqirvo than placebo in the double-blind period ...
Etiology and Treatment Advances of Hematochezia in Infants Aged ≤3 Months. Journal of Biosciences and Medicines, 12, 273-285. doi: 10.4236/jbm.2024.1211023 . Acute intussusception is most prevalent in ...